The EAA as a sub component of value From the Hmmmm article
Despite dramatic improvements in understanding the immunological mechanisms behind sepsis, it still remains a major medical concern, affecting 750,000 people in the U.S. and nearly 50 million people globally each year. Sepsis accounted for 11 million deaths worldwide in 2017, and is the most expensive medical condition in the U.S., costing over tens of billions of dollars annually.
If the world recognized that the EAA could be an effective triage tool to be used in ICUs to rule in, or out, Endotoxemia, perhaps millions of lives could be saved each year.
Spectral of course, owns the worldwide rights to this critical companion diagnostic ( the only FDA approved endotoxin diagnostic)
If there was JUST 1% penetration for this simple blood test to test for elevated levels of Endotoxins on 50 million patients...
that's 500,000 tests
@ $200
= $100million in annual revenues
approx $80m in EBiTDA
@10X
= $800M
per share on say 320 M shares
= $2.50 USD per share
= $3.37 CAD per share
...based on just 1% worldwide market penetration!!
remembering that Sepsis patients may get multiple tests, until the source of the infection is under control.
Heck even non septic patients would get tested if the present with respiratory or sepsis- like symptoms
and of course PMX patients would consume multiple EAAs.
Of course an FDA approval of PMX will give instant legitimacy to the EAA test.
MM